Compare Quest Diagnostics Inc (DGX) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs D R Horton Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while D R Horton Inc trades at $146.75 (market cap $42.18B). The key difference: D R Horton Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | DHI | |
|---|---|---|
Market Cap | $26.21B | $42.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $184.04 |
52-Week Low | $173.49 | $132.53 |
Enterprise Value | $31.97B | $47.28B |
Dividend Yield | 1.45% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
DHI trades at $146.49, down slightly by 0.12% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $3.20, beating estimates, but revenue guidance for FY2026 was lowered. Valuation ratios appear reasonable with a P/E of 14.37 and P/S of 1.31. Operating cash flow remains strong at $3.42B for 2025, though net cash flow was negative due to significant financing outflows.
The outlook is mixed; disciplined execution supports margins, but weak housing demand and elevated mortgage rates pose headwinds. Analyst consensus is a Buy with a $153 target, offering modest upside. Key risks include persistent affordability pressures and competitive threats from disruptors like Boxabl.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
